{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:09Z","timestamp":1784945829117,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[1997,3]]},"abstract":"<jats:p>\n            \u03b2-Blockers are known to slow the progression of diabetic nephropathy by lowering arterial pressure. Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect. To examine whether differential effects on proteinuria affect the progression of diabetic nephropathy, we conducted a randomized study that compared the effects of a heart rate\u2013lowering calcium channel blocker, sustained-release verapamil, with those of a \u03b2-blocker, atenolol, on the progression of diabetic renal disease. The primary end point of the study was a change in creatinine clearance slope. Thirty-four African Americans with the following inclusion criteria were randomized to one of the two groups: serum creatinine greater than 1.4 mg\/dL, proteinuria greater than 1500 mg\/d, longer than a 5-year history of both non\u2013insulin-dependent diabetes mellitus and hypertension, and exclusion of other renal diseases. Goal blood pressure was less than 140\/90 mm Hg. All subjects received loop diuretics as second line agents to help achieve the blood pressure goal. Twenty-four-hour urinary protein and sodium excretions as well as creatinine clearance were measured at 6-month intervals. Blood pressure was measured every 3 months. After a mean follow-up of 54\u00b16 months, the calcium channel blocker group demonstrated both a slower rate of decline in creatinine clearance (\u22121.7\u00b10.9 versus \u22123.7\u00b11.4 mL\/min per year per 1.73 m\n            <jats:sup>2<\/jats:sup>\n            ,\n            <jats:italic>P<\/jats:italic>\n            &lt;.01) and a greater reduction in proteinuria compared with the atenolol group. Additionally, a greater proportion of the atenolol group had a 50% or more increase in serum creatinine compared with the verapamil group (32\u00b19% versus 16\u00b17%,\n            <jats:italic>P<\/jats:italic>\n            &lt;.05). These between-group differences could not be explained by differences in blood pressure control. These data support the concept that antihypertensive agents that persistently maintain reductions in both arterial pressure and proteinuria slow the progression of diabetic renal disease in African Americans to a greater extent than those agents without these effects.\n          <\/jats:p>","DOI":"10.1161\/01.hyp.29.3.744","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:53:46Z","timestamp":1339462426000},"page":"744-750","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":106,"title":["Effect of Calcium Channel or \u03b2-Blockade on the Progression of Diabetic Nephropathy in African Americans"],"prefix":"10.1161","volume":"29","author":[{"given":"George L.","family":"Bakris","sequence":"first","affiliation":[{"name":"the Department of Medicine, Division of Nephrology, Ochsner Clinic, New Orleans, La (G.L.B., J.B.C., N.V., R.S.), and Rush University Hypertension Center, Rush-Presbyterian\/St Luke's Medical Center, Chicago, Ill (G.L.B., A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Mangrum","sequence":"additional","affiliation":[{"name":"the Department of Medicine, Division of Nephrology, Ochsner Clinic, New Orleans, La (G.L.B., J.B.C., N.V., R.S.), and Rush University Hypertension Center, Rush-Presbyterian\/St Luke's Medical Center, Chicago, Ill (G.L.B., A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Brian","family":"Copley","sequence":"additional","affiliation":[{"name":"the Department of Medicine, Division of Nephrology, Ochsner Clinic, New Orleans, La (G.L.B., J.B.C., N.V., R.S.), and Rush University Hypertension Center, Rush-Presbyterian\/St Luke's Medical Center, Chicago, Ill (G.L.B., A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Vicknair","sequence":"additional","affiliation":[{"name":"the Department of Medicine, Division of Nephrology, Ochsner Clinic, New Orleans, La (G.L.B., J.B.C., N.V., R.S.), and Rush University Hypertension Center, Rush-Presbyterian\/St Luke's Medical Center, Chicago, Ill (G.L.B., A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sadler","sequence":"additional","affiliation":[{"name":"the Department of Medicine, Division of Nephrology, Ochsner Clinic, New Orleans, La (G.L.B., J.B.C., N.V., R.S.), and Rush University Hypertension Center, Rush-Presbyterian\/St Luke's Medical Center, Chicago, Ill (G.L.B., A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490210061036"},{"key":"e_1_3_2_2_2","first-page":"1","volume":"42","year":"1993","unstructured":"Geiss LS, Herman WH, Goldschmid MG, DeStefano F, Eberhardt F, Eberhardt MS. Surveillance for diabetes mellitus: United States, 1980-1989. MMWR Morb Mortal Wkly Rep. 1993;42:1-20.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_3_2","first-page":"S187","volume":"8","year":"1990","unstructured":"Parving HH. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens.. 1990;8:S187-S191.","journal-title":"J Hypertens."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.361"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400110018005"},{"key":"e_1_3_2_7_2","first-page":"410","volume":"22","year":"1993","unstructured":"Walker WG, Hermann JA, Anderson JE. Randomized doubly blinded trial of enalapril vs hydrochlorothiazide on glomerular filtration rate in diabetic nephropathy. Hypertension.. 1993;22:410. Abstract.","journal-title":"Hypertension."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00040031707020"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1989.37"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Luft FC Miller JZ Grim CE. Salt sensitivity and resistance of blood pressure age and race as factors in physiological responses. Hypertension. 1991;17(suppl I):I-102-I-108.","DOI":"10.1161\/01.HYP.17.1_Suppl.I102"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(95)00335-5"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199605000-00006"},{"key":"e_1_3_2_13_2","unstructured":"Lash JP Bakris GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995;10(suppl 9):56-62."},{"key":"e_1_3_2_14_2","first-page":"1963","volume":"10","year":"1995","unstructured":"Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant.. 1995;10:1963-1974.","journal-title":"Nephrol Dial Transplant."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430100105012"},{"key":"e_1_3_2_16_2","unstructured":"Weidmann P Schneider M Bohlen L. Therapeutic efficacy of different anti-hypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant. 1995;10(suppl 9):39-45."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-3-199608010-00007"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04199.x"},{"key":"e_1_3_2_19_2","unstructured":"SAS Institute Inc. SAS\/STAT User's Guide Version 6. 4th ed. Cary NC: SAS Institute Inc; 1989;1:943."},{"key":"e_1_3_2_20_2","unstructured":"Statistical Sciences. S-PLUS User's Manual Version 3.2. Seattle Wash: StatSci division of MathSoft Inc; 1993:1-15."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440160050008"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410080037006"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6729.904"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199405000-00007"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.469"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Bakris GL Williams B. ACE inhibitors and calcium antagonists alone or combined: is there a difference on progression of diabetic renal disease? J Hypertens. 1995;13(suppl 2):S95-S101.","DOI":"10.1097\/00004872-199508001-00016"},{"key":"e_1_3_2_27_2","first-page":"1364","volume":"7","year":"1996","unstructured":"Smith AC, Bakris GL. Differential effects of calcium channel blockers on glomerular permeability in NIDDM patients: results of a two year study. J Am Soc Nephrol. 1996;7:1364. Abstract.","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117926"},{"key":"e_1_3_2_29_2","first-page":"245","volume":"10","year":"1996","unstructured":"Kesteloot H, Joossens JV. On the determinants of the creatinine clearance: a population study. J Hum Hypertens.. 1996;10:245-249.","journal-title":"J Hum Hypertens."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)81023-7"},{"key":"e_1_3_2_31_2","unstructured":"Toto RD Kirk KA Coresh J Jones C Appel L Wright J Campese V Olutade B Agodoa L and the AASK Pilot Study Investigators. Evaluation of serum creatinine for estimating glomerular filtration rate in blacks with hypertensive nephrosclerosis: results from the African-American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. In press."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90442-4"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188019"},{"key":"e_1_3_2_34_2","first-page":"1546","volume":"7","year":"1996","unstructured":"Bakris GL, Weir MR, DeQuattro V, Rosendorff C, MacMahon G. Renal hemo-dynamic and antiproteinuric response to an ACE inhibitor, trandolopril, or calcium antagonist, verapamil, alone or in fixed dose combination in patients with diabetic nephropathy: a randomized multicentered study. J Am Soc Nephrol. 1996;7:1546. Abstract.","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Bakris GL. Combination therapy for hypertension and renal disease in diabetes. In: Mogensen CE ed. The Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Boston Mass: Kluwer Academic Press; 1997:561-568.","DOI":"10.1007\/978-1-4757-6749-0_55"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.29.3.744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T17:19:18Z","timestamp":1715534358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.29.3.744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["10.1161\/01.HYP.29.3.744"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.29.3.744","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,3]]},"assertion":[{"value":"1996-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1997-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}